Cargando…

Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study

PURPOSE: Postembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Satoshi, Saiga, Atsushi, Yokota, Hajime, Kubota, Yoshihiro, Wada, Takeshi, Akutsu, Akira, Koizumi, Jun, Aramaki, Takeshi, Uno, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Interventional Radiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017270/
https://www.ncbi.nlm.nih.gov/pubmed/36936258
http://dx.doi.org/10.22575/interventionalradiology.2021-0015
_version_ 1784907543961665536
author Tsuchiya, Satoshi
Saiga, Atsushi
Yokota, Hajime
Kubota, Yoshihiro
Wada, Takeshi
Akutsu, Akira
Koizumi, Jun
Aramaki, Takeshi
Uno, Takashi
author_facet Tsuchiya, Satoshi
Saiga, Atsushi
Yokota, Hajime
Kubota, Yoshihiro
Wada, Takeshi
Akutsu, Akira
Koizumi, Jun
Aramaki, Takeshi
Uno, Takashi
author_sort Tsuchiya, Satoshi
collection PubMed
description PURPOSE: Postembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma (AML). MATERIAL AND METHODS: Between May 2004 and March 2020, 29 RAE procedures in 26 patients with AML were performed. Patient information, including age, sex, tumor size, tuberous sclerosis complex-associated/sporadic AML, hemorrhagic/nonhemorrhagic AML, embolic material, steroid use, medication type, some blood laboratory parameters, hospital stay, and PES occurrence were retrospectively obtained. The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks. After the discharge, intravenous prednisolone was changed to oral prednisolone (Predonine). PES was defined as the presence of fever, pain, nausea, or vomiting. Data were compared between the steroid and non-steroid groups and between PES and non-PES groups. RESULTS: The PES incidence rate was 76%, and a comparison between the steroid and non-steroid groups revealed that steroid use significantly decreased the incidence of PES (P < 0.001), including fever (P < 0.001), pain (P = 0.005), and nausea (P = 0.028). The use of anti-inflammatory drugs during the hospital stay was significantly lower in the steroid group (P = 0.019). Moreover, in the steroid group, C-reactive protein level was significantly lower (P = 0.006), whereas white blood cell count was significantly higher (P = 0.004). Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292). CONCLUSIONS: The prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study.
format Online
Article
Text
id pubmed-10017270
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Japanese Society of Interventional Radiology
record_format MEDLINE/PubMed
spelling pubmed-100172702023-03-16 Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study Tsuchiya, Satoshi Saiga, Atsushi Yokota, Hajime Kubota, Yoshihiro Wada, Takeshi Akutsu, Akira Koizumi, Jun Aramaki, Takeshi Uno, Takashi Interv Radiol (Higashimatsuyama) Original Research PURPOSE: Postembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma (AML). MATERIAL AND METHODS: Between May 2004 and March 2020, 29 RAE procedures in 26 patients with AML were performed. Patient information, including age, sex, tumor size, tuberous sclerosis complex-associated/sporadic AML, hemorrhagic/nonhemorrhagic AML, embolic material, steroid use, medication type, some blood laboratory parameters, hospital stay, and PES occurrence were retrospectively obtained. The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks. After the discharge, intravenous prednisolone was changed to oral prednisolone (Predonine). PES was defined as the presence of fever, pain, nausea, or vomiting. Data were compared between the steroid and non-steroid groups and between PES and non-PES groups. RESULTS: The PES incidence rate was 76%, and a comparison between the steroid and non-steroid groups revealed that steroid use significantly decreased the incidence of PES (P < 0.001), including fever (P < 0.001), pain (P = 0.005), and nausea (P = 0.028). The use of anti-inflammatory drugs during the hospital stay was significantly lower in the steroid group (P = 0.019). Moreover, in the steroid group, C-reactive protein level was significantly lower (P = 0.006), whereas white blood cell count was significantly higher (P = 0.004). Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292). CONCLUSIONS: The prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study. The Japanese Society of Interventional Radiology 2023-03-01 /pmc/articles/PMC10017270/ /pubmed/36936258 http://dx.doi.org/10.22575/interventionalradiology.2021-0015 Text en © 2023 Japanese Society of Interventional Radiology https://creativecommons.org/licenses/by-nc/4.0/Interventional Radiology is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original Research
Tsuchiya, Satoshi
Saiga, Atsushi
Yokota, Hajime
Kubota, Yoshihiro
Wada, Takeshi
Akutsu, Akira
Koizumi, Jun
Aramaki, Takeshi
Uno, Takashi
Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title_full Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title_fullStr Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title_full_unstemmed Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title_short Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study
title_sort prophylactic steroids for preventing postembolization syndrome after transcatheter arterial embolization of renal angiomyolipoma: a comparative study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017270/
https://www.ncbi.nlm.nih.gov/pubmed/36936258
http://dx.doi.org/10.22575/interventionalradiology.2021-0015
work_keys_str_mv AT tsuchiyasatoshi prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT saigaatsushi prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT yokotahajime prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT kubotayoshihiro prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT wadatakeshi prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT akutsuakira prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT koizumijun prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT aramakitakeshi prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy
AT unotakashi prophylacticsteroidsforpreventingpostembolizationsyndromeaftertranscatheterarterialembolizationofrenalangiomyolipomaacomparativestudy